Table 1.
Parameter | Water free (%) | p | Fat-free mass (%) | p | Fat mass (%) | p | BMI for age (kg/m2) | p | Phase angle (φ) | p |
---|---|---|---|---|---|---|---|---|---|---|
CG-Before | 59.26±3.28 | 0.0305* | 81.13±4.35 | 0.0080* | 18.87±4.35 | 0.0080* | 15.83±1.55 | 0.0563 | 5.31±0.64 | 0.1582 |
CG-After | 58.61±3.40 | 80.03±4.64 | 19.97±4.80 | 16.02±1.80 | 5.34±0.56 | |||||
EG-Before | 59.23±3.84 | 0.4979 | 81.00±5.29 | 0.3831 | 19.00±5.29 | 0.3831 | 15.92±1.76 | 0.0005* | 5.27±0.58 | 0.0470* |
EG-After | 59.10±3.50 | 80.74±4.85 | 19.26±4.85 | 16.33±2.03 | 5.39±0.65 | |||||
CG-Before | 59.26±3.28 | 0.7659 | 81.13±4.35 | 0.7231 | 18.87±4.35 | 0.7231 | 15.83±1.55 | 0.8455 | 5.31±0.64 | 0.9327 |
EG-Before | 59.23±3.84 | 81.00±5.29 | 19.00±5.29 | 15.92±1.76 | 5.27±0.58 | |||||
CG-Before | 59.26±3.28 | 0.8520 | 81.13±4.35 | 0.7419 | 18.87±4.35 | 0.7419 | 15.83±1.55 | 0.4856 | 5.31±0.64 | 0.4728 |
EG-After | 59.10±3.50 | 80.74±4.85 | 19.26±4.85 | 16.33±2.03 | 5.39±0.65 | |||||
CG-After | 58.61±3.40 | 0.3109 | 80.03±4.64 | 0.2166 | 19.97±4.80 | 0.2166 | 16.02±1.80 | 0.8230 | 5.34±0.56 | 0.6469 |
EG-Before | 59.23±3.84 | 81.00±5.29 | 19.00±5.29 | 15.92±1.76 | 5.27±0.58 | |||||
CG-After | 58.61±3.40 | 0.5829 | 80.03±4.64 | 0.5582 | 19.97±4.80 | 0.5582 | 16.02±1.80 | 0.6023 | 5.34±0.56 | 0.7227 |
EG-After | 59.10±3.50 | 80.74±4.85 | 19.26±4.85 | 16.33±2.03 | 5.39±0.65 |
Values are expressed as the means±SD
p<0.05.
Paired Student's t-tests were used to compare the data obtained within the control and experimental groups. Unpaired Student’ t-tests was used to compare the data obtained between both control and experimental groups. Control group before (CG-Before) and control group after (CG-After) represent before and after oral placebo administration, respectively. Experimental group before (EG-Before) and experimental group after (EG-After) represent before and after oral zinc supplementation, respectively.